Expression and clinical significance of long non-coding RNA SBF2-AS1 in non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2017.09.003
- VernacularTitle:长非编码RNA SBF2-AS1在非小细胞肺癌中的表达和临床意义
- Author:
Qi PENG
1
;
Fuping CHEN
;
Xiaomin DANG
Author Information
1. 726000,陕西省商洛市中心医院呼吸内科
- Keywords:
Lung neoplasms;
Pathology,clinical;
Biomarkers,pharmacological;
SBF2-AS1
- From:
Journal of International Oncology
2017;44(9):652-655
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and clinical significance of long non-coding RNA SBF2-AS1 (SBF2 antisense RNA 1) in non-small cell lung cancer (NSCLC).Methods Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect SBF2-AS1 expressions in 114 cases of NSCLC tissues and the adjacent normal tissues to analyze its relationship with clinic-pathological characteristics,diagnostic value and prognosis in NSCLC.Results SBF2-AS1 expression was significantly higher in the NSCLC (4.336 ±0.032) compared with the adjacent normal tissues (1.256 ± 0.021),with a significant difference (t =3.594,P =0.005).The expression of SBF2-AS1 was related with tumor size (x2 =13.072,P =0.001),lymphatic metastasis (x2 =6.896,P =0.009),TNM stage (x2 =8.566,P =0.003),smoking history (x2 =8.769,P =0.003) and infiltration degree (x2 =17.852,P =0.001),but was not related with age (x2 =0.141,P =0.707),sex (x2 =0.036,P =0.850) and pathological type (x2 =1.267,P =0.260).The area under the receiver operating characteristic (ROC) curve was 0.853 (95 ％ CI:0.755-0.879,P =0.004).The sensitivity and specificity was 52.4％ and 87.8％,respectively.The difference betwen low SBF2-AS1 expression and high SBF2-AS1 expression groups was statistically significant in overall survival time (42.3 months vs.25.2 months,x2 =4.753,P =0.013).Conclusion The expression of SBF2-AS1 is upregulated in NSCLC and may be proved useful as a biomarker and diagnostic target for the treatment of patients with NSCLC.
